SCHEMBL3660136

SCHEMBL3660136

CC1CN(Cc2ccc(B(O)O)cc2)CC(C)N1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.41
GPR119 Q8TDV5 3/20 0.36
JAK1 P23458 1/20 0.36
ABCB1 P08183 1/20 0.36
TP53 P04637 1/20 0.35
S1PR5 Q9H228 4/20 0.35
S1PR1 P21453 3/20 0.35
KCNK3 O14649 2/20 0.35
KCNK9 Q9NPC2 2/20 0.35
HRH4 Q9H3N8 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
TRPV1 Q8NER1 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
HSD11B1 P28845 1/20 0.34
VEGFA P15692 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31096238 0.86 GPR119 (0.42) GPR119JAK1ABCB1TP53S1PR5
SCHEMBL377569 0.85 GBA1 (0.41) GPR119JAK1ABCB1TP53S1PR5
SCHEMBL1703945 0.85 KCNK3 (0.44) GPR119S1PR1KCNK3KCNK9HRH3
SCHEMBL1704169 0.84 HRH3 (0.44) ABCB1S1PR5S1PR1HRH3HDAC1
SCHEMBL4595783 0.84 HRH3 (0.44) ABCB1S1PR5S1PR1HRH3HDAC1
SCHEMBL11978840 0.83 HDAC1 (0.36) GPR119JAK1ABCB1TP53S1PR5
SCHEMBL377504 0.83 PTPN2 (0.39) GPR119JAK1TP53KCNK3KCNK9
SCHEMBL16627299 0.82 GPR119 (0.50) CHRM4GPR119
SCHEMBL377559 0.81 ALDH1A1 (0.48)
SCHEMBL1704580 0.81 MLNR (0.41) GPR119JAK1S1PR5S1PR1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK CHRM4 213/4885GPR119 733/4885JAK1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.